Advancements in Nanoemulsion-Based Transdermal Systems for Enhanced Anticonvulsant Therapy in Chronic Neuropathic Pain
Priyanka Shinde, Jameel Ahmed S. Mulla
Abstract:
Neuropathic pain (NP) is a chronic ailment due to somatosensory system dysfunction, affecting 7–8% of the global population. Conventional oral anticonvulsants like gabapentin, pregabalin, and carbamazepine exhibit limitations, including poor bioavailability, systemic side effects, and patient non-compliance. Nanoemulsion-based transdermal delivery systems offer a novel approach to overcoming these challenges by enhancing drug solubility, stability, and skin penetration. These isotropic colloidal systems, with droplet sizes of 20–200 nm, incorporate oils, surfactants, and cosurfactants to bypass the gastrointestinal tract, reduce first-pass metabolism, and achieve sustained drug release. Formulation techniques such as ultrasonication, microfluidization, and spontaneous emulsification ensure stable and uniform nanoemulsions for efficient transdermal drug delivery. This strategy addresses the limitations of oral administration while minimizing systemic side effects, improving patient compliance, and enabling localized pain relief. Despite these advantages, challenges persist, including stability issues, scalability, and regulatory hurdles. Future innovations, such as smart nanoemulsions, personalized medicine approaches, and green formulations, are poised to transform chronic pain management and enhance therapeutic outcomes.
Keywords: Nanoemulsion, Neuropathic pain, Anticonvulsants, Nanoemulsion-based transdermal systems.
References:
[1] Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017; 3:17002.
[2] Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.
[3] Azanjac-Arsić. Neuropathic pain: Definition, classification and treatment. Galenika Med J. 2024;3(9):28-33.
[4] Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380–7.
[5] Kumari S, Kumar R, Sharma D. Text neck syndrome: the pain of modern era. Int J Health Sci Res. 2021;11(11):161-5.
[6] Sun J, Wang Y, Zhang X, Zhu S, He H. Prevalence of peripheral neuropathy in patients with diabetes: A systematic review and meta-analysis. Prim Care Diabetes. 2020;14(5):1-8.
[7] Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32. [8] Wong CS, Hui GK, Chung EK, Wong SH. Diagnosis and management of neuropathic pain. Pain Manag. 2014;4(3):221–31.
[9] Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10(11):1361–8.
[10] Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807–19.
[11] Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895-926.
[12] Kuner R, Flor H. Structural plasticity and reorganisation in chronic pain. Nat Rev Neurosci. 2016;18(1):20-30.
[13] Serpell MG; Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99(3):557-566.
[14] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and metaanalysis. Lancet Neurol. 2015;14(2):162- 173.
[15] Mulla JS, Pujari P, Sangar OS. An Overview of the Transdermal Drug Delivery System. Int J Creat Res Thoughts. 2022;10(5):a497- a507.
[16] Rana MH, Khan AAG, Khalid I, Ishfaq M, Javali MA, Baig FAH, et al. Therapeutic Approach for Trigeminal Neuralgia: A Systematic Review. Biomedicines. 2023;11(10):2606.
[17] Jadhav VU, Jamakandi VG, Mulla JA, Borkar SN, Karpe P, Suresh R, et al. Reservoir Type Nicorandil Transdermal Delivery System By Using Permeation Enhancers. Indian Drugs. 2009;46(9):23-31.
[18] Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57(3):505-509.
[19] Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr OpinPharmacol. 2006;6(1):108-113.
[20] Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473-481.
[21] Johannessen SI, Landmark CJ. Antiepileptic drug interactions – principles and clinical implications. Curr Neuropharmacol. 2010;8(3):254-267.
[22] Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246-255.
[23] Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68-82.
[24] Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792-802.
[25] Al-Aqeel S, Gershuni O, Al-Sabhan J, Hiligsmann M. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. Cochrane Database Syst Rev. 2020;10(10): CD008312.
[26] Shirke SN, Mulla JAS. Intranasal nanoemulsion for brain targeting: A review. Indian J Novel Drug Deliv. 2023;15(1):1-11.
[27] Kheradkar VA, Mulla JAS. Nanosuspension: A Novel Technology for Drug Delivery. Asian J Res Pharm Sci. 2023;13(2):106- 110.
[28] Chakorkar SS, Mulla JASG. Cubosome-based Corticosteroidal Drug Delivery System for Sustained Ocular Delivery: A Pharmacokinetic Investigation. Indian J Pharm Educ Res. 2024;58(2s):s502-s514.
[29] Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J Nanobiotechnol. 2008;6(1):8.
[30] McClements DJ. Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter. 2012;8(6):1719-29.
[31] Shaker DS, Ishak RAH, Ghoneim A, Elhuoni MA. Nanoemulsion: A Review on Mechanisms for the Transdermal Delivery of Hydrophobic and Hydrophilic Drugs. Sci Pharm. 2019;87(3):17.
[32] Kumar M, Bishnoi RS, Shukla AK, Jain CP. Techniques for Formulation of Nanoemulsion Drug Delivery System: A Review. Prev Nutr Food Sci. 2019;24(3):225-34.
[33] Mali JD, Mulla JAS. Ocular drug delivery system: A review. World J Drug Target. 2013;1(1):9-24.
[34] Chime SA, Kenechukwu FC, Attama AA. Nanoemulsions-Advances in Formulation, Characterization and Applications in Drug Delivery. In: Ali DS, editor. Application of Nanotechnology in Drug Delivery. Croatia: InTech; 2014. p. 77-111.
[35] Alhamdany TA, Saeed AMH, Alaayedi M. Nanoemulsion and Solid Nanoemulsion for Improving Oral Delivery of a Breast Cancer Drug: Formulation, Evaluation, and a Comparison Study. Saudi Pharm J. 2021;29(11):1278-88.
[36] Mhoprekar JD, Mulla JAS. Nanosponges drug delivery: A concise review. World J Nanopart Res. 2023;1(1):17-28.
[37] Shingate DM, Mulla JAS. Exploring Liposomes: Comprehensive Classification, Preparation Techniques, and Composition Insights. Indian J Novel Drug Deliv. 2024;16(2):80-90.
[38] Ghosh V, Mukherjee A, Chandrasekaran N. Ultrasonic emulsification of food-grade nanoemulsion formulation and evaluation of its bactericidal activity. UltrasonSonochem. 2013;20(1):338-44.
[39] Mulla JAS, Chalke PM, Londhe SP, Patil MA, Nalawade SN, Sawant RR. Design and Optimization of Nanosponges of Poorly Soluble Voriconazole Using Central Composite Design. Indian J Novel Drug Deliv. 2023;15(4):189-99.
[40] Mulla JAS, Khazi MIA, Khan AY, Gong YD, Khazi IAM. Design, Characterization and In vitro Evaluation of Imidazo[2,1- b][1,3,4]thiadiazole Derivative Loaded Solid Lipid Nanoparticles. Drug Invent Today. 2012;4(8):420-3.
[41] Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm. 2004;280(1-2):241-51.
[42] Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release. 2008;128(3):185-99.
[43] Mehanna MM, Mneimneh AT. Formulation and Applications of Lipid-Based Nanovehicles: Spotlight on Self-emulsifying Systems. Adv Pharm Bull. 2021;11(1):56- 67.
[44] Ganta S, Talekar M, Singh A, Coleman TP, Amiji MM. Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech. 2014;15(3):694-708.
[45] Pereira SF, Barroso A, Mourão RHV, Fernandes CP. A Low Energy Approach for the Preparation of Nano-Emulsions with a High Citral-Content Essential Oil. Molecules. 2021;26(12):3666.
[46] Roger K, Cabane B, Olsson U. Emulsification through surfactant hydration: the PIC process revisited. Langmuir. 2011;27(2):604-11.
[47] Tayeb HH, Felimban R, Almaghrabi S, Hasaballah N. Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks. Colloid Interface Sci Commun. 2021; 45:100533.
[48] Wolska J, Falizi NJ. Membrane Emulsification Process as a Method for Obtaining Molecularly Imprinted Polymers. Polymers. 2021;13(16):2830.
[49] Rai VK, Mishra N, Yadav KS, Yadav NP. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: Formulation development, stability issues, basic considerations and applications. J Control Release. 2018; 270:203-25.
[50] Bennett MI, Simpson KH. Gabapentin in the treatment of neuropathic pain. Palliat Med. 2004;18(1):5-11.
[51] Mishra VVBK, Bhanja SB, Panigrahi BB. Development and Evaluation of Nanoemulsion gel for transdermal delivery of Valdecoxib. Res J Pharm Tech. 2019;12(2):600-610.
[52] Hu W, Bian Q, Zhou Y, Gao J. Pain management with transdermal drug administration: A review. Int J Pharm. 2022; 618:121696.
[53] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-8.
[54] Hadgraft J. Skin, the final frontier. Int J Pharm. 2001;224(1-2):1-18.
[55] Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9(10):1263-71.
[56] Stark CW, Isaamullah M, Hassan SS, Dyara O, Abd-Elsayed A. A Review of Chronic Pain and Device Interventions: Benefits and Future Directions. Pain Ther. 2023;12(2):341-54.
[57] Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharm Res. 2007;24(7):1369-80.
[58] Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the Stratum Corneum. Pharmaceutics. 2015;7(4):438-70.
[59] Ruggiero A, Coccia P, Arena R, Maurizi P, Battista A, Ridola V, et al. Efficacy and safety of transdermal buprenorphine in the management of children with cancerrelated pain. Pediatr Blood Cancer. 2013;60(3):433-7.
[60] Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. Drugs. 2009;69(15):2149-65.
[61] McPherson ML, Cimino NM. Topical NSAID formulations. Pain Med. 2013;14 Suppl1:S35-9. [62] Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother. 2005;5(3):315-23.
[63] Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group. Controlled trial of highconcentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305-13.
[64] de Sire A, Marotta N, Lippi L, Scaturro D, Farì G, Liccardi A, et al. Pharmacological Treatment for Acute Traumatic Musculoskeletal Pain in Athletes. Medicina (Kaunas). 2021;57(11):1208.
[65] Wrzosek A, Woron J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J. Topical clonidine for neuropathic pain. Cochrane Database Syst Rev. 2015;8(8):CD010967.
[66] Choi SJ, McClements DJ. Nanoemulsions as delivery systems for lipophilic nutraceuticals: strategies for improving their formulation, stability, functionality and bioavailability. Food Sci Biotechnol. 2020;29(2):149-68.
[67] Bhansali D, Teng SL, Lee CS, Schmidt BL, Bunnett NW, Leong KW. Nanotechnology for Pain Management: Current and Future Therapeutic Interventions. Nano Today. 2021;39:101223.
[68] Pulingam T, Foroozandeh P, Chuah JA, Sudesh K. Exploring Various Techniques for the Chemical and Biological Synthesis of Polymeric Nanoparticles. Nanomaterials (Basel). 2022;12(3):576.
[69] Preeti, Sambhakar S, Malik R, Bhatia S, Al Harrasi A, Rani C, et al. Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs. Scientifica. 2023; 2023:6640103.
[70] Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: a novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2(3):238-57.
[71] Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023;9(6):e17488.
[72] Gu M, Wang X, Toh TB, Chow EK. Applications of stimuli-responsive nanoscale drug delivery systems in translational research. Drug Discov Today. 2018;23(5):1043-52.
[73] Jung JH, Jin SG. Microneedle for transdermal drug delivery: current trends and fabrication. J Pharm Investig. 2021;51(5):503-17.
[74] Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, et al. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics. 2024;16(10):1328.
[75] Kanwar R, Rathee J, Salunke DB, Mehta SK. Green Nanotechnology-Driven Drug Delivery Assemblies. ACS Omega. 2019;4(5):8804-15.
[76] Ganta S, Deshpande D, Korde A, Amiji M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol. 2010;27(7):260-73.
[77] Khadka B, Lee B, Kim KT. Drug Delivery Systems for Personal Healthcare by Smart Wearable Patch System. Biomolecules. 2023;13(6):929.
[78] Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.